Publications by authors named "J H Capdevila"
Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials.
Am J Med Genet C Semin Med Genet
January 2025
RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular-derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.
View Article and Find Full Text PDFNeuroendocrine carcinomas are rare and aggressive malignancies, often diagnosed at advanced stages, leading to poor prognosis. Platinum-based chemotherapy is the standard first-line treatment for advanced neuroendocrine carcinomas; however after achieving response no consensus exists on maintenance therapies and the results are inconsistent. This review examines the role of maintenance therapy following response to first-line chemotherapy in gastroenteropancreatic neuroendocrine carcinomas.
View Article and Find Full Text PDFArticle Synopsis
- The phase III KEYNOTE-913 study focused on assessing the effectiveness and safety of pembrolizumab as a first-line treatment for advanced Merkel cell carcinoma (MCC).
- Results indicated a 49% objective response rate among the 55 patients treated, with a median duration of response of 39.8 months and median overall survival of 24.3 months.
- The treatment showed manageable side effects, with 69% of patients experiencing any grade adverse events, but only 24% facing severe issues, highlighting pembrolizumab's potential in this patient group.
Article Synopsis
- Patients with advanced high-grade digestive neuroendocrine neoplasms (NENs) have a poor prognosis, but adding immune checkpoint inhibition to chemotherapy may improve their survival rates.
- The NICE-NEC trial tested nivolumab alongside carboplatin and etoposide in chemotherapy-naive patients and measured various outcomes, including overall survival and response rates.
- While the primary survival rate goal was not met, the treatment was linked to a median overall survival of 13.9 months and 37.6% of patients surviving more than 2 years, with manageable safety concerns.
Article Synopsis
- Nintedanib is a drug being tested for effectiveness against advanced thyroid cancers, specifically radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC), in a phase II clinical trial (EORTC-1209).
- The study compared nintedanib with a placebo for its effects on progression-free survival (PFS) among patients, showing a median PFS of 3.7 months for nintedanib vs. 2.9 months for placebo in the RAIR DTC cohort, although no objective responses were noted in either group.
- Adverse effects were more common in the nintedanib group, with about